Comparative Pharmacology
Head-to-head clinical analysis: SYNALAR HP versus TRIANEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNALAR HP versus TRIANEX.
SYNALAR-HP vs TRIANEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, altering gene expression to inhibit inflammatory mediators (e.g., prostaglandins, leukotrienes) and suppress immune cell activity.
Triamcinolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
Apply a thin film to the affected area once or twice daily for up to 2 weeks, using the lowest effective dose. Not for use under occlusive dressings or on large areas.
50 mg orally once daily.
None Documented
None Documented
Terminal half-life: 2-3 hours (topical) due to rapid clearance; systemic half-life: 1-2 hours
Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in severe hepatic impairment.
Renal: 90% as metabolites; biliary/fecal: minimal (<5%)
Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal elimination accounts for 20%; 10% metabolized to inactive metabolites.
Category C
Category C
Corticosteroid
Corticosteroid